How Long Do Reconstituted Peptides Last? What Stability Evidence Shows
Approved peptide labels give in-use limits from minutes to 30 days, set by stability studies of each formulation. Here is that evidence, and why it says nothing about research vials.
In this article
In-use periods are product facts, not peptide facts
A medicine’s label states how long it may be kept once dissolved or opened only after the manufacturer has tested that formulation, in that container, under the stated conditions. International stability guidance sets out how such studies are designed. The period is therefore a property of a product, not of a peptide in general. [5]
| Product | Form supplied | After reconstitution or first use | What drives the difference |
|---|---|---|---|
| EGRIFTA SV (tesamorelin) | Lyophilized powder with sterile water diluent | Use immediately; discard unused solution; do not refrigerate or freeze the solution | Single-use vial without a stated in-use period |
| GENOTROPIN 5 mg and 12 mg cartridges (somatropin) | Two-chamber cartridge, with preservative | Refrigerate at 2–8 °C for up to 28 days, protected from light | Multi-use cartridge containing a preservative |
| GENOTROPIN MINIQUICK (somatropin) | Two-chamber single-use device, without preservative | If needed, refrigerate for up to 24 hours; use once | Same molecule, no preservative, single use |
| BYETTA (exenatide) | Prefilled pen (solution) | After first use, up to 25 °C; discard 30 days after first use | Solution formulation in a multi-use pen |
| ZEPBOUND (tirzepatide) | Vial or KwikPen (solution) | Discard an opened multi-use vial or KwikPen after 30 days or after four weekly uses | Product-specific in-use limit |
The GENOTROPIN entries make the point most clearly: the same molecule from the same manufacturer has a 28-day limit in a preserved multi-use cartridge and a 24-hour limit in a single-use device without preservative. Formulation and container, not the peptide’s name, decide the answer. [2]
What this means for research vials
Research-labelled peptides are usually sold as a lyophilized powder with no stated formulation, excipients or container testing, and the solvent is chosen by the buyer. None of the approved-label periods above can be transferred to them. Where a seller gives a storage temperature, it is an instruction rather than a stability result; the example below states conditions but no duration. [6]
- Unknown: how long a dissolved research peptide stays within its stated purity or content, for any solvent, concentration or temperature.
- Unknown: whether a supplier’s storage statement rests on any stability testing, unless the supplier publishes the study.
- Not established by a certificate of analysis: what happens to the material after the sample was tested.
Figures such as “28 days” or “60 days” that circulate for research peptides are not supported by a published study of those products. A number taken from an approved medicine’s label describes that medicine only. [2][3][4]
Related definitions and guides
Glossary: lyophilized (freeze-dried) powder
Retatrutide storage: what suppliers state and what is unknown
Questions
Is there a standard shelf life for reconstituted peptides?
No. Approved peptide products list in-use limits ranging from immediate use to 30 days, each based on stability studies of that product’s formulation and container. There is no general figure that applies to peptides as a class.
Why do approved products list different in-use periods?
Because the period depends on the formulation, preservative, container and storage conditions tested. GENOTROPIN shows this within one product family: 28 days for preserved multi-use cartridges, up to 24 hours for the single-use device without preservative.
Does a supplier storage statement show how long a research peptide lasts?
No. A storage temperature from a seller is an instruction, and the pages reviewed did not cite stability data or state a duration. Without a published study of that product, its stability after dissolving is unknown.
Primary sources
Source checks recorded: Nov 5, 2026. Labels were read from DailyMed on 5 November 2026; each line paraphrases the label section cited. These are product-specific statements for approved medicines, given to show how in-use limits are set. They are not instructions and do not apply to any other product.
- DailyMed: EGRIFTA SV (tesamorelin) for injection, prescribing information (label effective 29 July 2026)FDA-approved product label · Checked Nov 5, 2026
- DailyMed: GENOTROPIN (somatropin) for injection, prescribing information section 16.2 (label effective 4 August 2026)FDA-approved product label · Checked Nov 5, 2026
- DailyMed: BYETTA (exenatide) injection, prescribing information section 16.2 (label effective 2 September 2025)FDA-approved product label · Checked Nov 5, 2026
- DailyMed: ZEPBOUND (tirzepatide) injection, storage and handling (label effective 28 August 2026)FDA-approved product label · Checked Nov 5, 2026
- ICH Q1A(R2): Stability testing of new drug substances and productsInternational regulatory guideline · Checked Nov 5, 2026
- American Peptides: retatrutide product page storage section (example supplier statement)Supplier product page · Checked Nov 5, 2026